Alnylam Pharmaceuticals (NASDAQ:ALNY) Lowered to Hold Rating by StockNews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Thursday.

Several other research firms also recently weighed in on ALNY. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Barclays upped their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Chardan Capital reiterated a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Bank of America boosted their price target on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $298.61.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $237.98 on Thursday. The company has a market capitalization of $30.69 billion, a P/E ratio of -90.83 and a beta of 0.34. The company has a 50-day simple moving average of $249.60 and a 200 day simple moving average of $259.41. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The firm’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.15 earnings per share. Sell-side analysts predict that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current fiscal year.

Insider Activity

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at $4,381,357.86. This represents a 8.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. The trade was a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock worth $2,540,455 in the last 90 days. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ALNY. Commonwealth Equity Services LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 2.8% during the second quarter. Commonwealth Equity Services LLC now owns 5,752 shares of the biopharmaceutical company’s stock worth $1,398,000 after buying an additional 158 shares during the last quarter. Ballentine Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $338,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $26,000. Andra AP fonden acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at $753,000. Finally, Daiwa Securities Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 3.4% in the second quarter. Daiwa Securities Group Inc. now owns 11,292 shares of the biopharmaceutical company’s stock valued at $2,744,000 after purchasing an additional 371 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.